Latest Regulatory News

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

PointsBet Holdings has secured Foreign Investment Review Board approval for MIXI Australia's proposed full acquisition, marking a key regulatory milestone in the takeover process.

BetMakers Technology Group has successfully raised $11.5 million through a share placement aimed at repaying debt and funding strategic growth initiatives, including a potential acquisition in Nevada.

Hazel Group Limited has temporarily paused trading of its securities on the ASX, signaling an impending announcement that investors will want to watch closely.

Hawsons Iron Ltd has been reinstated to ASX trading following an announcement of a proposed capital raising, signaling renewed investor interest.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

EV Resources Limited has finalized its acquisition of a 70% interest in the Los Lirios Antimony Mine in Oaxaca, Mexico, marking a strategic move to bolster critical mineral supply in the Americas. The company is advancing ore testing and plans to develop processing capabilities aligned with local community priorities.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.

Macquarie Group Limited has announced a quarterly ordinary dividend of AUD 1.7239 per CAP Note security, payable in September 2025, with partial franking and a total distribution rate of 6.84% per annum.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.